Tesamorelin Explained: How It Works, Research & Visceral Fat

Retatrutide Explained: How the Triple-Agonist Peptide Works & What Clinical Research Shows

Last Updated: August 2026

Retatrutide is an investigational peptide being studied for obesity, overweight, type 2 diabetes, and other metabolic conditions.

What makes retatrutide different is its unique triple-agonist mechanism. It activates three hormone receptors:

• GLP-1
• GIP
• Glucagon

Clinical research has produced significant weight-loss results, including an average 24.2% reduction in body weight after 48 weeks in a Phase 2 trial. More recent Phase 3 research has produced additional results.

However, retatrutide remains investigational and is not FDA-approved.

This guide explains what retatrutide is, how it works, what clinical research has found, and what researchers are studying next.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational once-weekly peptide developed by Eli Lilly.

It is called a “triple agonist” because it activates three different hormone receptors at the same time:

GLP-1 + GIP + Glucagon

This combination is what separates retatrutide from medications that target only one or two of these pathways.

How Does Retatrutide Work?

Retatrutide works through three major metabolic pathways.

GLP-1

GLP-1 signaling is involved in appetite regulation, glucose control, and gastrointestinal function.

GIP

GIP is a metabolic hormone involved in glucose and energy regulation.

Glucagon

Glucagon plays an important role in energy metabolism. Retatrutide’s activity at the glucagon receptor is one of the main features that distinguishes it from GLP-1-only and GLP-1/GIP therapies.

By activating all three pathways, researchers are studying retatrutide’s potential effects on appetite, food intake, glucose regulation, and energy metabolism.

Why Is Retatrutide Different?

The easiest way to understand the difference is to compare the major mechanisms:

Semaglutide
GLP-1

Tirzepatide
GLP-1 + GIP

Retatrutide
GLP-1 + GIP + Glucagon

Retatrutide’s triple-receptor activity is the defining feature of the molecule.

However, having a different mechanism does not automatically mean a treatment is better. Direct clinical comparisons are needed to determine how different therapies compare.

What Did Early Retatrutide Research Show?

One of the most important early studies was a randomized Phase 2 clinical trial published in the New England Journal of Medicine.

After 48 weeks, participants receiving the highest studied dose experienced an average 24.2% reduction in body weight, compared with 2.1% with placebo.

These results helped establish retatrutide as an important investigational therapy and supported the development of larger Phase 3 trials.

What Have Phase 3 Trials Found?

Retatrutide has now advanced into large Phase 3 clinical trials.

TRIUMPH-1

In the Phase 3 TRIUMPH-1 study, participants receiving 12 mg of retatrutide experienced an average 28.3% reduction in body weight after 80 weeks.

Lilly also reported that 45.3% of participants receiving 12 mg achieved at least 30% weight loss.

These were reported by Eli Lilly as Phase 3 topline results.

Other Phase 3 Research

Retatrutide is also being studied in people with:

• Type 2 diabetes
• Cardiovascular disease
• Obstructive sleep apnea
• Knee osteoarthritis
• Other metabolic conditions

These studies are helping researchers understand how retatrutide may perform across different populations and conditions.

Retatrutide vs. Semaglutide

Semaglutide primarily activates the GLP-1 receptor.

Retatrutide activates:

GLP-1 + GIP + Glucagon

This difference in mechanism is one reason retatrutide has attracted so much attention.

However, results from separate clinical trials should not be treated as direct comparisons. Head-to-head clinical trials provide stronger evidence when comparing treatments.

Retatrutide vs. Tirzepatide

Tirzepatide activates two receptors:

GLP-1 + GIP

Retatrutide activates three:

GLP-1 + GIP + Glucagon

The additional glucagon activity is the primary mechanistic difference between the two.

Researchers are studying retatrutide against tirzepatide in clinical trials to better understand how they compare.

What Are the Reported Side Effects?

Clinical trials have reported adverse events with retatrutide.

Gastrointestinal effects have been among the most commonly reported.

The Phase 2 trial also observed dose-dependent increases in heart rate.

Because retatrutide is still investigational, its complete long-term safety profile continues to be studied.

Is Retatrutide FDA Approved?

No.

As of August 2026, retatrutide has not been approved by the FDA.

Eli Lilly describes retatrutide as an investigational medicine that remains in clinical development.

Clinical-trial results should therefore not be confused with an FDA-approved indication.

Is Retatrutide Available to the Public?

Retatrutide is not currently an FDA-approved medication available through normal prescription channels.

Its use is being evaluated through clinical research.

Products marketed online as “retatrutide” may not have the same identity, purity, manufacturing controls, or quality standards as material used in clinical trials.

What Is the Future of Retatrutide?

Retatrutide has progressed from early-stage research into a broad Phase 3 development program.

Researchers are continuing to study:

• Long-term weight reduction
• Weight maintenance
• Type 2 diabetes
• Cardiovascular outcomes
• Obstructive sleep apnea
• Knee osteoarthritis
• Other metabolic conditions

Future clinical publications and regulatory decisions will provide additional information about retatrutide’s long-term effectiveness and safety.

Frequently Asked Questions

What is retatrutide?

Retatrutide is an investigational triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors.

How does retatrutide work?

Retatrutide activates three metabolic hormone receptors involved in appetite, glucose regulation, and energy metabolism.

How much weight loss has retatrutide produced in clinical trials?

In the Phase 2 trial, the highest studied dose produced an average 24.2% reduction in body weight after 48 weeks.

In the Phase 3 TRIUMPH-1 trial, Lilly reported an average 28.3% reduction after 80 weeks with 12 mg.

Is retatrutide the same as semaglutide?

No. Semaglutide primarily activates GLP-1, while retatrutide activates GLP-1, GIP, and glucagon receptors.

Is retatrutide the same as tirzepatide?

No. Tirzepatide activates GLP-1 and GIP receptors, while retatrutide activates GLP-1, GIP, and glucagon receptors.

Is retatrutide FDA approved?

No. Retatrutide remains investigational and is not currently FDA-approved.

Key Takeaways

Retatrutide is an investigational triple agonist targeting three metabolic pathways:

GLP-1 + GIP + Glucagon

Early Phase 2 research produced substantial weight-loss results, while newer Phase 3 research has reported even larger reductions.

In TRIUMPH-1, Lilly reported an average 28.3% reduction in body weight after 80 weeks with 12 mg.

Despite these promising results, retatrutide remains investigational and has not been approved by the FDA.

Continued clinical research will help determine its potential role in the future of metabolic medicine.

Explore Retatrutide Research

Interested in learning more about RTX-3?

Visit Vonox Labs to view additional product information.

VIEW RTX-3 20MG → RTX-3

Sources

Lilly — Retatrutide overview and current development status.

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.

Eli Lilly — Retatrutide clinical research and TRIUMPH program.

U.S. Food & Drug Administration — Information regarding unapproved GLP-1 drugs and retatrutide.